Core Viewpoint - The company, HAPO Pharmaceuticals-B (02142), experienced a significant stock price increase following the release of its interim financial results, highlighting strong revenue growth and strategic partnerships [1] Financial Performance - The company reported revenue of approximately $101 million, representing a year-on-year increase of about 327% [1] - Net profit for the period was $72.99 million, showing a remarkable year-on-year growth of 5,125% [1] - Revenue from molecular licensing fees rose from $20.8 million to $93.7 million, primarily due to strategic collaborations with global pharmaceutical companies and new licensing agreements for innovative products [1] - Research services and technology licensing fee income increased by 164.9%, from $2.9 million to $7.6 million [1] Strategic Partnerships - The company entered into a global strategic collaboration with AstraZeneca to co-develop next-generation multispecific antibodies targeting immune diseases, tumors, and other conditions, set to commence in March 2025 [1] - The collaboration includes the use of the company's proprietary fully human antibody technology platform, Harbour Mice, across multiple therapeutic areas [1] - In return for this partnership, the company is set to receive up to approximately $4.6 billion in upfront and milestone payments, along with tiered royalties based on net sales [1]
港股异动 | 和铂医药-B(02142)绩后涨近5%再创新高 BD交易显著提振业绩 公司上半年纯利同比增长51倍